Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored. Originally developed for the treatment of cancer, BsAbs may now benefit imaging and diagnostics, as well as disease prevention and treatment. Several bispecific antibodies have already obtained regulatory approval, while hundreds more are in development.
In this white paper, we will discuss the predominant formats and mechanisms of action of bispecific antibodies, the most common techniques for BsAbs transient production, and what is involved in their process development. We will also highlight the advantages of partnering with a CDMO with world-class service offerings, from discovery to production, and how doing so can ensure success of your BsAbs by delivering precise immunotherapy solutions and avoiding costly regulatory mistakes.
Ready to move from idea to impact?
Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.
Contact Us